Evotec (ETR:EVT) Stock Price Down 5% - What's Next?

Key Points

• Shares down ~5%: Evotec fell about 5% on Friday, trading as low as €5.31 and last at €5.40 with roughly 721,630 shares traded—about 47% below the average daily volume and down from a prior close of €5.69.
• Mixed financials: The company has a market cap of roughly $1.0 billion and a negative P/E (−5.84) indicating current losses, but shows solid liquidity (quick ratio 2.97, current ratio 2.07) alongside a debt-to-equity of 55.02 and 50/200-day moving averages of €5.06/€5.65.
• Business profile: Evotec is a drug discovery and development partner across many therapeutic areas and maintains collaborations with major pharma and biotech names, including Sanofi, Bristol Myers Squibb, Bayer, Exscientia and a strategic partnership with Dewpoint Therapeutics.

Evotec SE (ETR:EVT - ) shares dropped 5% during trading on Friday . The company traded as low as €5.31 and last traded at €5.40. Approximately 721,630 shares changed hands during trading, a decline of 47% from the average daily volume of 1,360,000 shares. The stock had previously closed at €5.69.

Evotec Stock Down 5.0%

The company has a quick ratio of 2.97, a current ratio of 2.07 and a debt-to-equity ratio of 55.02. The company has a market capitalization of $1.00 billion, a PE ratio of -5.84, a P/E/G ratio of 0.98 and a beta of 1.12. The stock has a 50-day moving average of €5.06 and a 200 day moving average of €5.65.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.